Jafron Biomedical Co

Jafron Biomedical Co OCF/Debt

The Operating Cash Flow to Debt Ratio of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is 60.95 %. In the previous year, Operating Cash Flow to Debt Ratio was 88.14 % — a change of -30.85% (lower).

OCF/Debt

60.95 %

YoY

-30.85%

Last updated:

Operating Cash Flow to Debt Ratio of Jafron Biomedical Co is 2025 60.95 % . Operating Cash Flow to Debt Ratio of Jafron Biomedical Co was 2024 88.14 % . It decreases by -30.85% lower compared to the previous year.

The Jafron Biomedical Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
358.38 CNY
Jan 1, 2019
978.19 CNY
Jan 1, 2020
3,166.48 CNY
Jan 1, 2021
136.17 CNY
Jan 1, 2022
69.27 CNY
Jan 1, 2023
55.42 CNY
Jan 1, 2024
88.14 CNY
Jan 1, 2025
60.95 CNY
The Jafron Biomedical Co OCF/Debt history
YEAROCF/DebtYoY
60.95 %-30.85%
88.14 %+59.04%
55.42 %-20.00%
69.27 %-49.13%
136.17 %-95.70%
3,166.48 %+223.71%
978.19 %+172.95%
358.38 %+61.92%
221.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Operating Cash Flow to Debt Ratio of Jafron Biomedical Co is 60.95 % in 2025.

Operating Cash Flow to Debt Ratio of Jafron Biomedical Co changed from 88.14 % to 60.95 %, representing a -30.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co